A specific VEGF-R tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in ErbB-2 overexpressing breast cancer cells

被引：0
|
作者：
Kim, E. [1 ]
Lobocki, C. A. [1 ]
Dubay, L. [1 ]
Mittal, V. [1 ]
机构：
[1] Providence Hosp, Med Ctr, Southfield, MI 48037 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2007年 / 14卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [1] A specific VEGF-R tyrosine kinase inhibitor enhances the anti proliferative effect of trastuzumab in ErbB-2 overexpressing breast cancer cells
    Kim, Elizabeth Min Hui
    Lobocki, Catherine
    Dubay, Linda
    Mittal, Vijay
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (03) : S94 - S95
  • [2] Inhibition of AKT signaling by targeting both VEGF-R and ErbB-2 in breast cancer cell lines
    Kim, Elizabeth Min Hui
    Lobocki, Catherine
    Van Dusen, Hillary
    Dubay, Linda
    CANCER RESEARCH, 2010, 70
  • [3] Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib
    De Luca, Antonella
    Faraso, Stefania
    D'Alessio, Amelia
    Gallo, Marianna
    Lamura, Luana
    Maiello, Monica R.
    Normanno, Nicola
    CANCER RESEARCH, 2011, 71
  • [4] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
    Martinello, Rossella
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Nuzzo, Annamaria
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
  • [5] HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
    Huang, Xiaoping
    Wang, Shuiliang
    Lee, Choon-Kee
    Yang, XiaoHe
    Liu, Bolin
    CANCER LETTERS, 2011, 307 (01) : 72 - 79
  • [6] Lapatinib, a dual ErbB-1/ErbB-2 kinase inhibitor, in the treatment of HER2-overexpressing locally advanced and metastatic breast cancer
    不详
    CLINICAL BREAST CANCER, 2006, 7 (03) : 224 - 227
  • [7] Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors—a novel antiproliferative/antiangiogenic strategy in thyroid cancer
    S. Hoffmann
    S. Gläser
    A. Wunderlich
    S. Lingelbach
    C. Dietrich
    A. Burchert
    H. Müller
    M. Rothmund
    A. Zielke
    Langenbeck's Archives of Surgery, 2006, 391 : 589 - 596
  • [8] Targeting of ErbB3 with functional cooperative miRNAs enhances efficacy of trastuzumab in ErbB2-overexpressing breast cancer cells
    Lyu, Hui
    Huang, Jingcao
    Wang, Bolun
    Han, Amy
    Liu, Bolin
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors -: a novel antiproliferative/antiangiogenic strategy in thyroid cancer
    Hoffmann, S.
    Glaeser, S.
    Wunderlich, A.
    Lingelbach, S.
    Dietrich, C.
    Burchert, A.
    Mueller, H.
    Rothmund, M.
    Zielke, A.
    LANGENBECKS ARCHIVES OF SURGERY, 2006, 391 (06) : 589 - 596
  • [10] A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the anti proliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines
    Kim, Elizabeth M. H.
    Lobocki, Catherine
    Dubay, Linda
    Mittal, Vijay K.
    AMERICAN JOURNAL OF SURGERY, 2009, 197 (03): : 331 - 335
12345